# Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

> **NCT00712348** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Taliglucerase alfa

## Key facts

- **NCT ID:** NCT00712348
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712348, "Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00712348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*